The financials
Penumbra, Inc. by the numbers
Penumbra, Inc. (PEN) reported revenue of $375M in Q1 2026 (quarter ended March 31, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $33M (8.7% of revenue). For the full year FY2025, revenue was $1.40B (+17% year on year) and net income $178M. Its largest product in 2026-Q1 was Thrombectomy at $254M, 68% of the disclosed total, just ahead of Embolization And Access at 32%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $375M | $324M | +16% |
| Gross profit | $253M | $216M | +17% |
| Operating income | $38M | $40M | −5.2% |
| Net income | $33M | $39M | −17% |
| Diluted EPS | $0.82 | $1.00 | −18% |
| Product | Revenue | Share |
|---|---|---|
| Thrombectomy | $254M | 68% |
| Embolization And Access | $121M | 32% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $374.8M (+5.7%)
Embolization And Access grew +24% year on yearThrombectomy +12% year on year
Segment Latestquarter on quarteryear on year
- Thrombectomy$253.9M$253.9MQoQ +7.4%year on year +12%+7.4%+12%
- Embolization And Access$120.8M$120.8MQoQ +2.2%year on year +24%+2.2%+24%
Medical Devices
Ranks #19 of 35 by Smart Score